Project Grant R15CA301412
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $421K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Institutes of Health's National Cancer Institute awarded Saint Joseph's University $869,996 under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the role of the CAPER protein in DNA damage and repair pathways in triple negative breast cancer. The three-year project grant will fund research to delineate CAPER's influence on basal DNA damage and repair mechanisms in triple negative breast cancer cells using both immunocompromised and immunocompetent...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $395,356 to Georgetown University to conduct research on the mechanisms and pathways of glucocorticoid receptor (GR) signaling in triple negative breast cancer (TNBC) progression. The project aims to examine how communication between "enabler" and "responder" cells in TNBC enhances the GR response, leading to increased invasion and metastasis. Specifically, the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- The University of South Alabama was awarded a $369,868 Project Grant from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) on July 7, 2025. The grant supports research to investigate the functional role of the intercellular transfer of mitochondria between nerves and cancer cells, particularly in the context of triple-negative breast cancer metastasis. The key objectives of the 5-year project are to: 1) Determine the contribution of nerve-to-cancer mitochondrial transfer in...
- This $781,436 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Cold Spring Harbor Laboratory to optimize anti-NMDAR (N-methyl-D-aspartate receptor) antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen for anti-NMDAR antibodies that can effectively target NMDAR-positive TNBC cells while...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- The National Cancer Institute awarded a $134,274 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Tufts University School of Medicine in Boston, MA. The goal of this 3.5-year project, starting December 1, 2024 and ending June 30, 2028, is to investigate the role of the TRPV1 ion channel in driving increased sensory nerve innervation within triple-negative breast cancer (TNBC) tumors. The research aims to uncover the mechanism by which TNBC cells stimulate...
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...